文献速递乳腺US

超声应变弹性成像与超声造影预测乳腺癌新辅助化疗疗效:整合Ki-67与超声特征的列线图

Ultrasound Strain Elastography and Contrast-Enhanced Ultrasound in Predicting the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: A Nomogram Integrating Ki-67 and Ultrasound Features.
PubMed 文献 · J Ultrasound Med · 2021-12-10

研究纳入2010年2月至2015年11月接受新辅助化疗的91例乳腺癌患者,评估最大径、硬度及超声造影特征并结合Ki-67构建列线图预测病理完全缓解。基线大小联合超声造影特征、硬度及Ki-67的AUC为0.821,将特征变化量纳入多因素回归后AUC达0.986。

要点

  • 最大径变化与Miller-Payne评分相关(P<.05),可用于评估残留病灶。
  • 基线Ki-67在病理完全缓解组显著高于非完全缓解组(P=.029)。
  • 联合基线大小、超声造影特征、硬度及Ki-67的AUC为0.821(P=.004)。

核心结论

  • 最大径变化与Miller-Payne评分相关,可辅助预测新辅助化疗疗效并评估残留病灶;联合弹性成像、超声造影及Ki-67能更好地预测病理反应。

研究设计与样本

  • 回顾性纳入2010年2月至2015年11月接受新辅助化疗的91例乳腺癌患者,评估最大径、硬度及超声造影特征,并行核心穿刺活检、手术病理免疫表型及Miller-Payne评估,采用ROC分析和逻辑回归分析。

关键影像表现/征象

  • 基线最大径预测病理完全缓解的敏感度57.40%、特异度70.30%、AUC 0.64(P=.024)。
  • 基线Ki-67预测病理完全缓解的敏感度51.70%、特异度78.00%、AUC 0.638(P=.050)。

诊断标准与关键数值

  • 基线大小预测病理完全缓解:敏感度57.40%、特异度70.30%、AUC 0.64(P=.024)。
  • 基线Ki-67预测病理完全缓解:敏感度51.70%、特异度78.00%、AUC 0.638(P=.050)。
  • 基线大小联合超声造影特征、硬度及Ki-67预测病理完全缓解:敏感度70.00%、特异度76.19%、AUC 0.821(P=.004)。
  • 将特征变化量纳入多因素回归分析:敏感度100.00%、特异度95.24%、AUC 0.986(P=.000)。

临床应用与阅片要点

  • 最大径变化与Miller-Payne评分相关(P<.05),可用于预测新辅助化疗疗效并评估残留病灶。
  • 联合弹性成像、超声造影及Ki-67可提高预测病理反应的效能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To explore whether conventional elastography and contrast-enhanced ultrasound (CEUS) combined with histopathology can monitor the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer (BC), and develop a Nomogram prediction model monitoring response to NAC.

METHODS: From February 2010 to November 2015, 91 BC patients who received NAC were recruited. The maximum diameter, stiffness, and CEUS features were assessed. Core biopsy, surgical pathology immunophenotype, and Miller-Payne (MP) evaluation were documented. Univariate and multivariate analysis was performed using receiver operating characteristic (ROC) analysis and logistic regression analysis.

RESULTS: There were 37 cases showing pathological complete response (pCR) and 54 of non-pCR. The changes of maximal diameter were correlated with MP (P < .05). The sensitivity (SEN), specificity (SPE), and area under the ROC curve (AUC) of baseline size predicting pCR were 57.40%, 70.30%, and 0.64 (P = .024). Baseline Ki-67 index of pCR group is significantly higher than that of non-pCR group (P = .029), and the ROC analysis of baseline Ki-67 indicates the SEN, SPE, and AUC of 51.70%, 78.00%, and 0.638 (P = .050). When combined with size, CEUS features, stiffness, and Ki-67 of baseline, the ROC curve shows good performance with SEN, SPE, and AUC of 70.00%, 76.19%, 0.821 (P = .004). Incorporating the change of characteristics into multivariate regression analysis, the results demonstrate excellent performance (SEN 100.00%, SPE 95.24%, AUC 0.986, P = .000).

CONCLUSIONS: The change of the maximum size was correlated with MP score, which can provide reference to predict efficacy of NAC and evaluate residual lesions. When combining with elastography, CEUS, and Ki-67, better performance in predicting pathological response was shown.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Liu, Tang, Chen, et al. Ultrasound Strain Elastography and Contrast-Enhanced Ultrasound in Predicting the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: A Nomogram Integrating Ki-67 and Ultrasound Features. J Ultrasound Med. 2021. PMID: 34888900. doi:10.1002/jum.15900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。